myself to match the changing expectations of the Organization. I believe WHO's human resources are key to attaining its mandate. As a member of the HR team, I contribute to the efforts to attract, retain and motivate WHO's staff members in our Region
without PrEP, versus the demand with two million patients on PrEP. This additional demand for PrEP .... Sciences estimated that more than 79,000 people in the US have started Truvada for PrEP since July. 2012.8 Adoption of PrEP was ...... General of
statistical framework; the data series is up to date. 13. 5. Methods for assessing country health information system performance. The principal goal of the GDDS is to improve data quality, which relates both to the data themselves but also to the sta
The mention of specific companies or of certain manufacturers' products does not imply .... dents, marital stress, work-related stress, and depression or anxiety due to job loss, ... These efforts are largely focused on low- and middle- .... in DALYs
1.2 Size and nature of the disease burden ............................................................................................. 8 1.2.1 Europe .............................................................................................................................................. 8 1.2.2 Worldwide .................................................................................................................................... 12 2.
Control Strategy ........................................................................................................................................ 15 2.1
Why Does the Disease Burden Persist? ................................................................................................ 21
4.
Lessons From Research Into Pharmaceutical Interventions For Pneumonia ................................ 22 4.1 Antibiotics.......................................................................................................................................... 22 4.1.1 Treatment for children ................................................................................................................. 22 4.1.2 Treatment for the elderly............................................................................................................. 24 4.2 Vaccines ............................................................................................................................................. 25 4.2.1 Prevention for children ................................................................................................................ 25 4.2.2 Prevention for the elderly ........................................................................................................... 27 4.3
References........................................................................................................................................................... 37 Annexes ............................................................................................................................................................... 40 Annex 6.22.1: Global mortality for all causes of death and pneumonia among children under five, 1990-2010. ........................................................................................................................................................ 41 Annex 6.22.2: Under five deaths due to pneumonia by regions, 2010. .................................................. 41
6.22-2
Update on 2004 Background Paper, BP 6.22 Pneumonia Annex 6.22.3: Mortality for all ages due to pneumococcal disease by European regions and the world, 2010. .................................................................................................................................................... 42 Annex 6.22.4: Compapretive effectiveness of antibiotics on community acquired pneumonia death in children under 18 years of age................................................................................................................. 43 Annex 6.22.5: Pneumococcal conjugate vaccine in preventing vaccine-serotypes invasive pneumococcal disease in children